Navigation Links
DNAtrix, Inc. to Present Clinical Study Results for DNX-2401 (Delta 24-RGD), A Conditionally Replication-Competent Adenovirus
Date:6/17/2013

HOUSTON, June 17, 2013 /PRNewswire/ -- DNAtrix Inc., experts in oncolytic virus development, today announced that its CEO will present clinical data on the company's lead product, DNX-2401, at the Replicating Oncolytic Virus Therapeutic meeting in Quebec City, Canada on June 18, 2013.

Dr. Frank Tufaro, DNAtrix's CEO and a leader in the field of oncolytic virus therapy, will present results from a clinical study entitled A PHASE I TRIAL OF A CONDITIONALLY REPLICATION-COMPETENT ADENOVIRUS DNX-2401 (FORMERLY KNOWN AS DELTA-24-RGD) FOR RECURRENT MALIGNANT GLIOMAS that evaluated DNX-2401 for patients diagnosed with recurrent glioblastoma. Dr. Tufaro will present study data indicating that DNX-2401 has been well tolerated in 37 patients with no dose-limiting toxicity. Additionally, DNX-2401 has demonstrated highly impressive activity and efficacy.

"We are extremely pleased to have participated in bringing DNX-2401 into the clinic, and are encouraged by the results from this clinical study," said Dr. Tufaro. "DNX-2401 has not only revealed a positive safety profile but also an ability to selectively kill glioblastoma cells. This is exciting because it can lead to complete tumor destruction."

About Glioblastoma and DNX-2401
Glioblastoma is a devastating primary brain tumor resistant to conventional therapies and the second most common cause of death from intracranial disease. The lack of effective therapy for brain tumors has led to intense investigations of novel therapeutic approaches that use vectors and recombinant viruses. Oncolytic virus therapy is based on the concept of using live viruses to selectively infect and replicate in cancer cells, with minimal destruction of normal tissue. Replication amplifies the input dose of the oncolytic virus and helps spread the agent to adjacent tumor cells. DNX-2401, a conditionally replication-competent adenovirus, is being developed for the treatment of several cancer indications including patients with recurrent glioblastoma. DNX-2401 is the culmination of more than a decade of scientific and clinical research and is the most potent and effective oncolytic virus delivered to human brain tumors to date.  DNAtrix will initiate a Phase II clinical study later this year.

About DNAtrix, Inc.
DNAtrix is a company developing modified viruses for the treatment of the most aggressive forms of cancer. Since viruses are already efficient at killing cells, scientists have harnessed this ability by modifying a common cold virus so that it targets and selectively kills cancer cells. DNAtrix is a privately held company located in Houston, Texas and San Diego, California. For more information, please visit the Company's website at http://www.dnatrix.com.

DNAtrix, Inc. Contact
Frank Tufaro, Ph.D.
Chief Executive Officer
ftufaro@dnatrix.com
(858) 342-6577


'/>"/>
SOURCE DNAtrix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
2. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
3. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
4. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
5. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
7. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
8. Hospira to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
9. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
10. Anlit to Present New Dietary Supplements for Children at Vitafoods Europe 2012
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... TUCSON, Ariz. , May 3, 2016  As ... twice contracted rheumatic fever, which damaged his heart. ... But by June 2013, Shepherd,s heart was ... days from death. On June 20, 2013, the ... temporary Total Artificial Heart (TAH-t). Like a heart transplant, ...
(Date:5/3/2016)... , May 3, 2016  While you may be familiar with watching a film or ... also known as ultra-high-definition or 8MP in the Medical Industry.  Ampronix  is a renowned authorized ... innovative technology. Photo - http://photos.prnewswire.com/prnh/20160502/362730 ... ... ...
(Date:5/3/2016)... , May 3, 2016 Pharmaceutical ... $55 million to a woman who says its talc-based ... awarded Gloria Ristesund $5 million in compensatory ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... against the company. In February, the same court awarded ...
Breaking Medicine Technology:
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... Dr. Benjamin ... in non-surgical hair loss treatment. Dr. Stong is double board certified and the ... for the treatment of hair loss. Non-surgical therapies such as stem cells can ...
(Date:5/5/2016)... San Rafael, CA (PRWEB) , ... May 05, 2016 , ... ... Coach of the Year, Derek Pittman, along with his university coaching staff. Together they ... and girls, with separate sessions run for youth players ages 5-13, and high school ...
(Date:5/5/2016)... CA (PRWEB) , ... May 05, 2016 , ... ... may not seem like an intuitive activity to alleviate the pain that’s a ... effective in improving pain and function in people with arthritis. , “Physical ...
(Date:5/5/2016)... , ... May 05, 2016 , ... The Lung Institute will celebrate its ... a seminar at most clinic locations throughout the month of May. To date, the Lung ... “The rapid growth that we’ve seen is a testament to the success of this treatment ...
(Date:5/5/2016)... N.J. (PRWEB) , ... May 05, 2016 , ... ... patients with cancer, today announced a new collaboration with Imerman Angels to ... cancer anywhere in the world. , “Imerman Angels provides an emotional lifeline to patients ...
Breaking Medicine News(10 mins):